申请人:Neurogen Corporation, A Corporation of the State of Delaware
公开号:US20030216379A1
公开(公告)日:2003-11-20
Heterocyclic compounds such as 3,4,5,6-tetrahydro-2,3,10-triaza-benzo[e]azulene-1-carboxylic acid arylamides, 5,7-Dihydro-6H-pyrazolo[3,4-h]quinoline-9-carboxylic acid arylamides, 5,7-Dihydro-6H-pyrazolo[3,4-h]quinazoline-9-carboxylic acid arylamides, 2,4,5,6-Tetrahydro-1,2,6,7-tetraaza-as-indacene-8-carboxylic acid arylamides and related compounds are disclosed. These compounds are highly selective agonists, antagonists or inverse agonists for GABA
A
brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABA
A
brain receptors and are therefore useful in the treatment of anxiety, depression, sleep and seizure disorders, overdose with benzodiazepine drugs, Alzheimer's dementia, and for enhancement of memory. Pharmaceutical compositions, including packaged pharmaceutical compositions, are further provided. Intermediates useful for the synthesis of pyrazolecarboxylic acid arylamides are also provided. Compounds of the invention are also useful as probes for the localization of GABA
A
receptors in tissue samples.
本发明涉及杂环化合物,例如3,4,5,6-四氢-2,3,10-三氮杂苯[ e ]蓝-1-羧酸芳基酰胺,5,7-二氢-6H-吡唑并[3,4-h]喹啉-9-羧酸芳基酰胺,5,7-二氢-6H-吡唑并[3,4-h]喹唑啉-9-羧酸芳基酰胺,2,4,5,6-四氢-1,2,6,7-四氮杂萘-8-羧酸芳基酰胺及相关化合物。这些化合物是高选择性的GABAA脑受体激动剂、拮抗剂或反向激动剂,或者是GABAA脑受体激动剂、拮抗剂或反向激动剂的前药,因此对于焦虑、抑郁、睡眠和癫痫障碍、苯二氮平类药物过量、阿尔茨海默病和增强记忆等方面的治疗是有用的。此外,还提供了包括包装的制药组合物在内的制药组合物。还提供了用于合成吡唑酸芳基酰胺的中间体。本发明的化合物还可用作组织样品中GABAA受体的定位探针。